249 related articles for article (PubMed ID: 34641722)
21. Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer.
Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M
Cancer Chemother Pharmacol; 2018 Oct; 82(4):649-654. PubMed ID: 30051190
[TBL] [Abstract][Full Text] [Related]
22. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract][Full Text] [Related]
23. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments antitumor activity in melanoma.
Tran TT; Caulfield J; Zhang L; Schoenfeld D; Djureinovic D; Chiang VL; Oria V; Weiss SA; Olino K; Jilaveanu LB; Kluger HM
JCI Insight; 2023 Apr; 8(7):. PubMed ID: 36821392
[TBL] [Abstract][Full Text] [Related]
25. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
De Lisi D; De Giorgi U; Lolli C; Schepisi G; Conteduca V; Menna C; Tonini G; Santini D; Farolfi A
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):461-467. PubMed ID: 29557694
[TBL] [Abstract][Full Text] [Related]
26. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
[TBL] [Abstract][Full Text] [Related]
27. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma.
Huang Y; Du Z; Kan A; He M; Li H; Lai Z; Wen D; Huang L; Li Q; Xu L; Shi M
Front Immunol; 2024; 15():1260191. PubMed ID: 38384459
[TBL] [Abstract][Full Text] [Related]
28. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
[TBL] [Abstract][Full Text] [Related]
29. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Schlumberger M; Jarzab B; Cabanillas ME; Robinson B; Pacini F; Ball DW; McCaffrey J; Newbold K; Allison R; Martins RG; Licitra LF; Shah MH; Bodenner D; Elisei R; Burmeister L; Funahashi Y; Ren M; O'Brien JP; Sherman SI
Clin Cancer Res; 2016 Jan; 22(1):44-53. PubMed ID: 26311725
[TBL] [Abstract][Full Text] [Related]
30. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.
Tahara M; Schlumberger M; Elisei R; Habra MA; Kiyota N; Paschke R; Dutcus CE; Hihara T; McGrath S; Matijevic M; Kadowaki T; Funahashi Y; Sherman SI
Eur J Cancer; 2017 Apr; 75():213-221. PubMed ID: 28237867
[TBL] [Abstract][Full Text] [Related]
31. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
32. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
[TBL] [Abstract][Full Text] [Related]
33. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma.
Yang J; Guo Z; Song M; Pan Q; Zhao J; Huang Y; Han Y; Ouyang D; Yang C; Chen H; Di M; Tang Y; Zhu Q; Wang Q; Li Y; He J; Weng D; Xiang T; Xia J
Front Immunol; 2023; 14():1212577. PubMed ID: 37545530
[TBL] [Abstract][Full Text] [Related]
34. High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.
Lee CH; DiNatale RG; Chowell D; Krishna C; Makarov V; Valero C; Vuong L; Lee M; Weiss K; Hoen D; Morris L; Reznik E; Murray S; Kotecha R; Voss MH; Carlo MI; Feldman D; Sachdev P; Adachi Y; Minoshima Y; Matsui J; Funahashi Y; Nomoto K; Hakimi AA; Motzer RJ; Chan TA
Mol Cancer Res; 2021 Sep; 19(9):1510-1521. PubMed ID: 34039647
[TBL] [Abstract][Full Text] [Related]
35. Drug safety evaluation of lenvatinib for thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
[TBL] [Abstract][Full Text] [Related]
36. Rapid disease progression after discontinuation of lenvatinib in thyroid cancer.
Yamazaki H; Sugino K; Matsuzu K; Masaki C; Akaishi J; Hames K; Tomoda C; Suzuki A; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Masuda M; Ito K
Medicine (Baltimore); 2020 Mar; 99(11):e19408. PubMed ID: 32176066
[TBL] [Abstract][Full Text] [Related]
37. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma.
Deng H; Kan A; Lyu N; He M; Huang X; Qiao S; Li S; Lu W; Xie Q; Chen H; Lai J; Chen Q; Jiang X; Liu S; Zhang Z; Zhao M
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34168004
[TBL] [Abstract][Full Text] [Related]
38. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
[TBL] [Abstract][Full Text] [Related]
39. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
40. siRNA targeting PD-L1 delivered with attenuated Salmonella enhanced the anti-tumor effect of lenvatinib on mice bearing Hepatocellular carcinoma.
Chen P; Li Y; Wei P; Liang L; Li B; Cao Y; Han X; Wang Y; Duan X; Jia H; Zhao T; Ren J
Int Immunopharmacol; 2022 Oct; 111():109127. PubMed ID: 35964407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
